Targeting apoptosis in solid tumors: the role of bortezomib from preclinical to clinical evidence. (Q37004739)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18020979 AND SRC:MED&resulttype=core&format=json

26 December 2019

review article

1 reference

title

Targeting apoptosis in solid tumors: the role of bortezomib from preclinical to clinical evidence (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18020979 AND SRC:MED&resulttype=core&format=json

26 December 2019

0 references

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18020979 AND SRC:MED&resulttype=core&format=json

26 December 2019

Giuseppe Cicero

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18020979 AND SRC:MED&resulttype=core&format=json

26 December 2019

Bruno Vincenzi

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18020979 AND SRC:MED&resulttype=core&format=json

26 December 2019

Giuseppe Tonini

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18020979 AND SRC:MED&resulttype=core&format=json

26 December 2019

Daniele Santini

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18020979 AND SRC:MED&resulttype=core&format=json

26 December 2019

3

Viviana Bazan

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18020979 AND SRC:MED&resulttype=core&format=json

26 December 2019

2

Maria E Fratto

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18020979 AND SRC:MED&resulttype=core&format=json

26 December 2019

author name string

Antonio Russo

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18020979 AND SRC:MED&resulttype=core&format=json

26 December 2019

Valentina Schiró

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18020979 AND SRC:MED&resulttype=core&format=json

26 December 2019

language of work or name

English

0 references

publication date

1 December 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18020979 AND SRC:MED&resulttype=core&format=json

Expert Opinion on Therapeutic Targets

26 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18020979 AND SRC:MED&resulttype=core&format=json

26 December 2019

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18020979 AND SRC:MED&resulttype=core&format=json

26 December 2019

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18020979 AND SRC:MED&resulttype=core&format=json

26 December 2019

page(s)

1571-1586

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18020979 AND SRC:MED&resulttype=core&format=json

The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction

26 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

The 26S proteasome: a molecular machine designed for controlled proteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

Activation of the cell death program by inhibition of proteasome function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

Development of the proteasome inhibitor PS-341.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

Proteasome inhibition: a novel approach to cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

Distinct regulation of Ubc13 functions by the two ubiquitin-conjugating enzyme variants Mms2 and Uev1A

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

The proteasome: structure, function, and role in the cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

The proteasome and the delicate balance between destruction and rescue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

The proteasome: a novel target for cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

The ubiquitin-proteasome pathway and proteasome inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

Altering protein turnover in tumor cells: new opportunities for anti-cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

Ubiquitin as a central cellular regulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

Discovery of the ubiquitin proteasome system and its involvement in apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

Control of apoptosis by p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

NF-kappa B as a therapeutic target in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

The IKK NF-kappa B system: a treasure trove for drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

The Bcl2 family: regulators of the cellular life-or-death switch

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

TRAIL and its receptors as targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

TRAIL and apoptosis induction by TNF-family death receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

JNK and AP-1 mediate apoptosis induced by bortezomib in HepG2 cells via FasL/caspase-8 and mitochondria-dependent pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

Antimyeloma activity of heat shock protein-90 inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

Use of methotrexate-based peptide substrates to characterize the substrate specificity of prostate-specific membrane antigen (PSMA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

TNF potentiates anticancer activity of bortezomib (Velcade) through reduced expression of proteasome subunits and dysregulation of unfolded protein response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

Proteasome-regulated ERBB2 and estrogen receptor pathways in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

p53-dependent apoptosis induced by proteasome inhibition in mammary epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

Protease inhibitors restore radiation-induced apoptosis to Bcl-2-expressing lymphoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

Inhibition of proteasome function induced apoptosis in gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

Proteasome inhibitors induced caspase-dependent apoptosis and accumulation of p21WAF1/Cip1 in human immature leukemic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK/c-Jun/AP-1 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

Involvement of the interaction between p21 and proliferating cell nuclear antigen for the maintenance of G2/M arrest after DNA damage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

Clinical update: proteasome inhibitors in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

Phase II trial of bortezomib for patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

A phase II study of bortezomib in the treatment of metastatic malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

Use of bortezomib in B-cell non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

The emerging role of targeted therapy for hematologic malignancies: update on bortezomib and tipifarnib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571

United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.12.1571